{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T19:21:05Z","timestamp":1776453665660,"version":"3.51.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Mississippi has one of the highest rates of HIV in the United States but low PrEP uptake. Understanding patterns of PrEP use can improve PrEP initiation and persistence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This is a mixed-method evaluation of a PrEP program in Jackson, Mississippi. Between November 2018-December 2019, clients at high risk for HIV attending a non-clinical testing site were referred to a pharmacist for same-day PrEP initiation. The pharmacist provided a 90-day PrEP prescription and scheduled a follow-up clinical appointment within three months. We linked client records from this visit to electronic health records from the two largest PrEP clinics in Jackson to determine linkage into ongoing clinical care. We identified four distinct PrEP use patterns, which we used for qualitative interview sampling: 1) filled a prescription and linked into care within three months; 2) filled a prescription and linked into care after three months; 3) filled a prescription and never linked into care; and 4) never filled a prescription. In 2021, we purposively sampled patients in these four groups for individual interviews to ascertain barriers and facilitators to PrEP initiation and persistence, using guides informed by the Theory of Planned Behavior.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were 121 clients evaluated for PrEP; all were given a prescription. One-third were less than 25\u00a0years old, 77% were Black, and 59% were cisgender men who have sex with men. One-quarter (26%) never filled their PrEP prescription, 44% picked up the prescription but never linked into clinical care, 12% linked into care at some point after three months (resulting in a gap in PrEP coverage), and 18% linked into care within 3\u00a0months. We interviewed 26 of 121 clients. Qualitative data revealed that cost, stigmas related to sexuality and HIV, misinformation about PrEP, and perceived side effects were barriers to uptake and persistence. Individuals\u2019 desire to stay healthy and the support of PrEP clinic staff were facilitators.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The majority of individuals given a same-day PrEP prescription either never started PrEP or stopped PrEP within the first three months. Addressing noted barriers of stigma and misinformation and reducing structural barriers may increase PrEP initiation and persistence.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-023-16072-1","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T06:02:03Z","timestamp":1686636123000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Persistence in a pharmacist-led, same-day PrEP program in Mississippi: a mixed-methods study"],"prefix":"10.1186","volume":"23","author":[{"given":"Christine M.","family":"Khosropour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Riley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Healy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kandis V.","family":"Backus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney E.","family":"Gomillia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leandro","family":"Mena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khadijra R.","family":"Lockwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felicia M.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arianna R.","family":"Means","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori M.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"16072_CR1","unstructured":"Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data United States and 6 dependent areas, 2019. 2021. Available from: https:\/\/www.cdc.gov\/hiv\/pdf\/library\/reports\/surveillance\/cdc-hiv-surveillance-report-vol-26-no-2.pdf. Accessed 12 Jan 2022."},{"issue":"4","key":"16072_CR2","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S2352-3018(22)00030-3","volume":"9","author":"J Zhang","year":"2022","unstructured":"Zhang J, Li C, Xu J, Hu Z, Rutstein SE, Tucker JD, et al. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022;9(4):e254\u201368.","journal-title":"The lancet HIV"},{"issue":"Suppl 3","key":"16072_CR3","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s10461-019-02654-x","volume":"23","author":"CP Rolle","year":"2019","unstructured":"Rolle CP, Onwubiko U, Jo J, Sheth AN, Kelley CF, Holland DP. PrEP implementation and persistence in a county health department setting in Atlanta, GA.\u00a0 AIDS Behav. 2019;23(Suppl 3):296\u2013303.","journal-title":"GA AIDS and behavior"},{"issue":"1","key":"16072_CR4","doi-asserted-by":"publisher","first-page":"20903","DOI":"10.7448\/IAS.19.1.20903","volume":"19","author":"PA Chan","year":"2016","unstructured":"Chan PA, Mena L, Patel R, Oldenburg CE, Beauchamps L, Perez-Brumer AG, et al. Retention in care outcomes for HIV pre-exposure prophylaxis implementation programmes among men who have sex with men in three US cities. J Int AIDS Soc. 2016;19(1):20903.","journal-title":"J Int AIDS Soc"},{"issue":"8","key":"16072_CR5","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1089\/apc.2019.0054","volume":"33","author":"ME Clement","year":"2019","unstructured":"Clement ME, Johnston BE, Eagle C, Taylor D, Rosengren AL, Goldstein BA, et al. Advancing the HIV pre-exposure prophylaxis continuum: a collaboration between a public health department and a federally qualified health center in the Southern United States. AIDS Patient Care STDS. 2019;33(8):366\u201371.","journal-title":"AIDS Patient Care STDS"},{"issue":"5","key":"16072_CR6","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1007\/s12325-020-01295-0","volume":"37","author":"KH Mayer","year":"2020","unstructured":"Mayer KH, Agwu A, Malebranche D. Barriers to the wider use of pre-exposure prophylaxis in the United States: a narrative review. Adv Ther. 2020;37(5):1778\u2013811.","journal-title":"Adv Ther"},{"key":"16072_CR7","doi-asserted-by":"crossref","unstructured":"Bonacci RA, Smith DK, Ojikutu BO. Toward greater pre-exposure prophylaxis equity: increasing provision and uptake for Black and Hispanic\/Latino Individuals in the U.S. Am J Prev Med. 2021;61(5 Suppl 1):S60\u2013S72.","DOI":"10.1016\/j.amepre.2021.05.027"},{"issue":"7","key":"16072_CR8","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1007\/s10461-020-03156-x","volume":"25","author":"S Russ","year":"2021","unstructured":"Russ S, Zhang C, Liu Y. Pre-exposure prophylaxis care continuum, barriers, and facilitators among black men who have sex with men in the United States: a systematic review and meta-analysis. AIDS Behav. 2021;25(7):2278\u201388.","journal-title":"AIDS Behav"},{"issue":"10279","key":"16072_CR9","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0140-6736(21)00396-2","volume":"397","author":"AA Adimora","year":"2021","unstructured":"Adimora AA, Ramirez C, Poteat T, Archin NM, Averitt D, Auerbach JD, et al. HIV and women in the USA: what we know and where to go from here. Lancet. 2021;397(10279):1107\u201315.","journal-title":"Lancet"},{"issue":"2","key":"16072_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0172354","volume":"12","author":"T Arnold","year":"2017","unstructured":"Arnold T, Brinkley-Rubinstein L, Chan PA, Perez-Brumer A, Bologna ES, Beauchamps L, et al. Social, structural, behavioral and clinical factors influencing retention in Pre-Exposure Prophylaxis (PrEP) care in Mississippi. PLoS One. 2017;12(2): e0172354.","journal-title":"PLoS ONE"},{"issue":"4","key":"16072_CR11","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/S2352-3018(22)00036-4","volume":"9","author":"JL Marcus","year":"2022","unstructured":"Marcus JL, Krakower DS. Making PrEP easy. Lancet HIV. 2022;9(4):e226\u20138.","journal-title":"The lancet HIV"},{"key":"16072_CR12","unstructured":"Centers for Disease Control and Prevention. HIV surveillance report, 2020; vol. 33. 2022. Available from: https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance\/vol-33\/index.html. Accessed 13 June 2022."},{"issue":"9","key":"16072_CR13","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2019.1343","volume":"321","author":"AS Fauci","year":"2019","unstructured":"Fauci AS, Redfield RR, Sigounas G, Weahkee MD, Giroir BP. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321(9):844\u20135.","journal-title":"JAMA"},{"key":"16072_CR14","unstructured":"Mississippi State Department of Health. Ending the HIV Epidemic: Epidemiologic Profile 2018. 2021."},{"key":"16072_CR15","unstructured":"US Census Bureau. Quick facts: Mississippi 2019. Available from: https:\/\/www.census.gov\/quickfacts\/MS. Accessed 25 May 2021."},{"key":"16072_CR16","unstructured":"Feeding America. Hunger in America study 2014. Available from:\u00a0https:\/\/www.feedingamerica.org\/research\/hunger-in-america. Accessed 21 May 2021."},{"key":"16072_CR17","unstructured":"Princeton Eviction Lab. Eviction lab map & data. 2016. Available from:\u00a0https:\/\/evictionlab.org\/. Accessed 12 May 2021."},{"key":"16072_CR18","unstructured":"AIDSVu. AIDSVu 2022. Available from: https:\/\/aidsvu.org. Accessed 21 Apr 2022."},{"issue":"12","key":"16072_CR19","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.annepidem.2018.06.005","volume":"28","author":"AJ Siegler","year":"2018","unstructured":"Siegler AJ, Mouhanna F, Giler RM, Weiss K, Pembleton E, Guest J, et al. The prevalence of pre-exposure prophylaxis use and the pre-exposure prophylaxis-to-need ratio in the fourth quarter of 2017,\u00a0United States.\u00a0 Ann Epidemiol. 2018;28(12):841\u20139.","journal-title":"United States Annals of epidemiology"},{"issue":"1","key":"16072_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/apc.2019.0235","volume":"34","author":"CM Khosropour","year":"2020","unstructured":"Khosropour CM, Backus KV, Means AR, Beauchamps L, Johnson K, Golden MR, et al. A pharmacist-led, same-day, hiv pre-exposure prophylaxis initiation program to increase prep uptake and decrease time to PrEP initiation. AIDS Patient Care STDS. 2020;34(1):1\u20136.","journal-title":"AIDS Patient Care STDS"},{"key":"16072_CR21","doi-asserted-by":"crossref","unstructured":"Edmonds WA, Kennedy TD. Explanatory-Sequential Approach. In: Edmonds WA, Kennedy TD, editors. An applied guide to research designs: quantitative, qualitative, and mixed methods. Los Angeles: SAGE Publications, Inc.; 2017.","DOI":"10.4135\/9781071802779"},{"key":"16072_CR22","unstructured":"National Alliance of State Pharmacy Associations. Collaborative Practice Agreements: Resources and More 2017 [updated June 8, 2017. Available from: https:\/\/naspa.us\/resource\/cpa\/."},{"key":"16072_CR23","unstructured":"Mississippi Secretary of State. Title 30 part 3001: Mississippi pharmacy practice regulations. Available from: https:\/\/sos.ms.gov\/ACProposed\/00022001b.pdf. Accessed 29 Aug 2022."},{"key":"16072_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019;95: 103208.","journal-title":"J Biomed Inform"},{"issue":"2","key":"16072_CR25","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"16072_CR26","unstructured":"Sadinle M. BRL: Beta Record Linkage. 2020 [updated January 13, 2020]. Available from:\u00a0https:\/\/CRAN.R-project.org\/package=BRL. Accessed 1 Sept 2021."},{"key":"16072_CR27","doi-asserted-by":"crossref","unstructured":"Ajzen I. From intentions to actions: A theory of planned behavior. In: Beckmann JKJ, editor. Action-control: From cognition to behavior Heidelberg: Springer; 1985. p. 11\u201339.","DOI":"10.1007\/978-3-642-69746-3_2"},{"issue":"2","key":"16072_CR28","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/0749-5978(91)90020-T","volume":"50","author":"I Ajzen","year":"1991","unstructured":"Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991;50(2):179\u2013211.","journal-title":"Organ Behav Hum Decis Process"},{"key":"16072_CR29","doi-asserted-by":"crossref","unstructured":"Ayangeakaa SD, Kerr J, Combs R, Harris L, Sears J, Parker K, et al. Understanding Influences on Intention to Use Pre-exposure Prophylaxis (PrEP) Among African American Young Adults. J Racial Ethn Health Disparities. 2022.","DOI":"10.1007\/s40615-022-01278-7"},{"issue":"6","key":"16072_CR30","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1080\/09540121.2021.1874267","volume":"33","author":"NK Tran","year":"2021","unstructured":"Tran NK, Felsher M, Pol BV, Bellamy SL, McKnight J, Roth AM. Intention to initiate and uptake of PrEP among women who injects drugs in a demonstration project: an application of the theory of planned behavior. AIDS Care. 2021;33(6):746\u201353.","journal-title":"AIDS Care"},{"issue":"1","key":"16072_CR31","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/QAI.0000000000001724","volume":"79","author":"S Doblecki-Lewis","year":"2018","unstructured":"Doblecki-Lewis S, Liu AY, Feaster DJ, Cohen SE, Elion R, Bacon O, et al. Patterns and correlates of participant retention in a multi-city pre-exposure prophylaxis demonstration project. J Acquir Immune Defic Syndr. 2018;79(1):62\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"16072_CR32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1093\/cid\/ciz894","volume":"71","author":"DP Serota","year":"2020","unstructured":"Serota DP, Rosenberg ES, Sullivan PS, Thorne AL, Rolle CM, Del Rio C, et al. Pre-exposure prophylaxis uptake and discontinuation among young black men who have sex with men in Atlanta, Georgia: a prospective cohort study. Clin Infect Dis. 2020;71(3):574\u201382.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"16072_CR33","doi-asserted-by":"publisher","first-page":"e62","DOI":"10.1097\/OLQ.0000000000000823","volume":"45","author":"JC Dombrowski","year":"2018","unstructured":"Dombrowski JC, Golden MR, Barbee LA, Khosropour CM. Patient disengagement from an hiv preexposure prophylaxis program in a sexually transmitted disease clinic. Sex Transm Dis. 2018;45(9):e62\u20134.","journal-title":"Sex Transm Dis"},{"issue":"3","key":"16072_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/JNC.0000000000000070","volume":"30","author":"CJ Park","year":"2019","unstructured":"Park CJ, Taylor TN, Gutierrez NR, Zingman BS, Blackstock OJ. Pathways to HIV Pre-exposure prophylaxis among women prescribed prep at an urban sexual health clinic. J Assoc Nurses AIDS Care. 2019;30(3):321\u20139.","journal-title":"J Assoc Nurses AIDS Care"},{"issue":"1","key":"16072_CR35","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1186\/s12879-021-06786-1","volume":"21","author":"TC Willie","year":"2021","unstructured":"Willie TC, Monger M, Nunn A, Kershaw T, Stockman JK, Mayer KH, et al. \u201cPrEP\u2019s just to secure you like insurance\u201d: a qualitative study on HIV pre-exposure prophylaxis (PrEP) adherence and retention among black cisgender women in Mississippi. BMC Infect Dis. 2021;21(1):1102.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"16072_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11904-019-00447-4","volume":"16","author":"PS Sullivan","year":"2019","unstructured":"Sullivan PS, Mena L, Elopre L, Siegler AJ. Implementation strategies to increase PrEP uptake in the South. Curr HIV\/AIDS Rep. 2019;16(4):259\u201369.","journal-title":"Curr HIV\/AIDS Rep"},{"issue":"11","key":"16072_CR37","doi-asserted-by":"publisher","first-page":"3588","DOI":"10.1007\/s10461-018-2076-7","volume":"22","author":"PW Schnarrs","year":"2018","unstructured":"Schnarrs PW, Gordon D, Martin-Valenzuela R, Sunil T, Delgado AJ, Glidden D, et al. Perceived social norms about oral prep use: differences between african-american, latino and white gay, bisexual and other men who have sex with men in Texas. AIDS Behav. 2018;22(11):3588\u2013602.","journal-title":"AIDS Behav"},{"issue":"10","key":"16072_CR38","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1007\/s10461-020-02843-z","volume":"24","author":"BO Ojikutu","year":"2020","unstructured":"Ojikutu BO, Amutah-Onukagha N, Mahoney TF, Tibbitt C, Dale SD, Mayer KH, et al. HIV-related mistrust (or HIV conspiracy theories) and willingness to use prep among black women in the United States. AIDS Behav. 2020;24(10):2927\u201334.","journal-title":"AIDS Behav"},{"key":"16072_CR39","unstructured":"Shapiro A. Ending HIV in Mississippi means cutting through racism, poverty and homophobia. 2019. Available from: https:\/\/www.npr.org\/sections\/health-shots\/2019\/03\/16\/696862618\/ending-hiv-in-mississippi-means-cutting-through-racism-poverty-and-homophobia. Accessed 28 Aug 2022."},{"issue":"8","key":"16072_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.22692","volume":"4","author":"JC Hojilla","year":"2021","unstructured":"Hojilla JC, Hurley LB, Marcus JL, Silverberg MJ, Skarbinski J, Satre DD, et al. Characterization of HIV preexposure prophylaxis use behaviors and hiv incidence among us adults in an integrated health care system. JAMA Netw Open. 2021;4(8): e2122692.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"16072_CR41","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/cid\/ciy810","volume":"68","author":"AY Liu","year":"2019","unstructured":"Liu AY, Vittinghoff E, von Felten P, Rivet Amico K, Anderson PL, Lester R, et al. Randomized controlled trial of a mobile health intervention to promote retention and adherence to preexposure prophylaxis among young people at risk for human immunodeficiency virus: the EPIC study. Clin Infect Dis. 2019;68(12):2010\u20137.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"16072_CR42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1089\/apc.2017.0255","volume":"32","author":"JD Fuchs","year":"2018","unstructured":"Fuchs JD, Stojanovski K, Vittinghoff E, McMahan VM, Hosek SG, Amico KR, et al. A mobile health strategy to support adherence to antiretroviral preexposure prophylaxis. AIDS Patient Care STDS. 2018;32(3):104\u201311.","journal-title":"AIDS Patient Care STDS"},{"issue":"10","key":"16072_CR43","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1093\/cid\/cix1055","volume":"66","author":"DJ Moore","year":"2018","unstructured":"Moore DJ, Jain S, Dube MP, Daar ES, Sun X, Young J, et al. Randomized controlled trial of daily text messages to support adherence to preexposure prophylaxis in individuals at risk for human immunodeficiency virus: the TAPIR study. Clin Infect Dis. 2018;66(10):1566\u201372.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"16072_CR44","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/QAI.0000000000002954","volume":"90","author":"WC Goedel","year":"2022","unstructured":"Goedel WC, Coats CS, Chan PA, Sims-Gomillia CE, Brock JB, Ward LM, et al. A pilot study of a patient navigation intervention to improve hiv pre-exposure prophylaxis persistence among black\/African American men who have sex with men. J Acquir Immune Defic Syndr. 2022;90(3):276\u201382.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"23","key":"16072_CR45","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1056\/NEJMoa1506273","volume":"373","author":"JM Molina","year":"2015","unstructured":"Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015;373(23):2237\u201346.","journal-title":"N Engl J Med"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-16072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-023-16072-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-023-16072-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T06:02:13Z","timestamp":1686636133000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-023-16072-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["16072"],"URL":"https:\/\/doi.org\/10.1186\/s12889-023-16072-1","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"7 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All study procedures and analyses were reviewed and approved by the University of Washington and University of Mississippi Medical Center Institutional Review Boards (IRB) and carried out in accordance with relevant guidelines and regulations. The RapidPrEP program was a clinical program, and not a research activity. Individuals who received a PrEP prescription in this program were not part of a research study; thus, written informed consent was not required for their participation in the PrEP program. The University of Washington IRB and the University of Mississippi Medical Center IRB waived informed consent for the quantitative analysis of data for this study (which was a medical records review). The quantitative portion of the study included data from individuals who were 16\u201317 at the time they received PrEP from the Rapid PrEP program. In Mississippi, individuals aged 16\u201317 can seek sexual health care without parental consent and can participate in sexual health related research without parental consent. Thus, informed consent from a parent and\/or legal guardian was waived by the University of Washington IRB and University of Mississippi Medical Center IRB. For the qualitative component of the study, informed consent was obtained from all the individuals who were interviewed. The University of Washington IRB and University of Mississippi Medical Center IRB approved the informed verbal consent procedure. Interviewed participants were all adults (at least 18\u00a0years old), so informed consent from a parent and\/or legal guardian was not required for study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"n\/a","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.M.K. has received donations of specimen collection kits and reagents from Hologic, Inc. for research studies outside the submitted work. K.V.B is currently employed by Gilead Sciences. Employment began after the completion of client enrollment in RapidPrEP. All other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1130"}}